BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

New drug research partnership aims to deliver $1 malaria prevention shot

22 July 2025 | News

Eyam Health, a Canadian biotech, and Medicines for Malaria Venture (MMV) will work together to develop new cost-effective next-generation monoclonal antibody-based antimalarials, using Eyam's advanced biologics technology.



Eyam Health and Medicines for Malaria Venture (MMV) are excited to announce a strategic research partnership to discover and evaluate next- generation monoclonal antibody-based approaches for affordable, long-acting malaria therapies. This could be a game changer in accelerating MMV's strategic ambitions to build the next generation of life- saving antimalarials in the face of increasing drug resistance.

The collaboration will harness Eyam's groundbreaking technologies to transform how monoclonal antibodies are developed and delivered. The Jennerator platform uses advanced AI to rapidly design next-generation biologics, while the Gemini system enables those therapies to be delivered with unmatched durability, without cold storage, and at a fraction of the traditional cost. Importantly, Gemini can carry multiple antibodies at once in a single dose—making it possible to target multiple stages of the parasite's lifecycle.

Gemini platform has ability to carry multiple therapeutics and deliver them together in a single shot—for less than $1 per dose. A single long-acting injection could protect over 50 million young children and pregnant women for the entire rainy season (typically 4-5 months) during peak malaria transmission. It would significantly simplify seasonal malaria chemoprevention (SMC), improve compliance and support further expansion, complementing the current suite of prevention tools including bed nets, vaccines and vector control. Importantly for pandemic preparedness, the Gemini platform as a nucleic acid-based technology will be readily adapted for local African manufacturing.

Monoclonal antibodies have been considered a potential alternative technology for antimalarials thanks to their favourable potency, durability of response and safety profile. However, to date, monoclonal antibodies have had limited exposure in global public health due to their high cost of production. Eyam Health's proprietary technology, Gemini, dispenses with the need for expensive lipid nanoparticles (LNPs)2 . Together with the extended dosage interval this makes it an attractive technology to evaluate in resource-limited settings.

Eyam Health and MMV are committed to advancing healthcare solutions that are both effective and economically viable. This

partnership underscores their dedication to addressing global health challenges with innovative technology and improving the lives of those affected by malaria and beyond.